Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome
about
Effect of oligonucleotide primers in determining viral variability within hostsHepatitis C virus molecular evolution: transmission, disease progression and antiviral therapyViral quasispecies evolutionWide range of quasispecies diversity during primary hepatitis C virus infectionAn Interplay between Hypervariable Region 1 of the Hepatitis C Virus E2 Glycoprotein, the Scavenger Receptor BI, and High-Density Lipoprotein Promotes both Enhancement of Infection and Protection against Neutralizing AntibodiesMonoclonal Antibody AP33 Defines a Broadly Neutralizing Epitope on the Hepatitis C Virus E2 Envelope GlycoproteinCharacterization of hepatitis C virus quasispecies by matrix-assisted laser desorption ionization-time of flight (mass spectrometry) mutation detection.Hepatitis C Virus NS3 ATPases/Helicases from Different Genotypes Exhibit Variations in Enzymatic PropertiesViral Determinants of Resistance to Treatment in Patients with Hepatitis CGenetic distance and heterogenecity between quasispecies is a critical predictor to IFN response in Egyptian patients with HCV genotype-4Monitoring of Hepatitis C Virus Quasispecies in Chronic Infection by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry Mutation DetectionThe West Nile virus mutant spectrum is host-dependant and a determinant of mortality in miceInfluence of increased CD4 cell counts on the genetic variability of hepatitis C virus in patients co-infected with human immunodeficiency virus IGenetic variation in West Nile virus from naturally infected mosquitoes and birds suggests quasispecies structure and strong purifying selectionCorrelation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3aHepatitis C virus envelope glycoprotein co-evolutionary dynamics during chronic hepatitis CInvestigation of Putative Multisubtype Hepatitis C Virus Infections In Vivo by Heteroduplex Mobility Analysis of Core/Envelope SubgenomesGenetic Variability of Hepatitis C Virus before and after Combined Therapy of Interferon plus RibavirinInfluence of quasispecies on virological responses and disease severity in patients with chronic hepatitis CFull-Length Characterization of Hepatitis C Virus Subtype 3a Reveals Novel Hypervariable Regions under Positive Selection during Acute InfectionThe quasispecies nature and biological implications of the hepatitis C virusHepatitis C Virus (HCV) Quasispecies Complexity and Selection in HCV/HIV‐Coinfected Subjects Treated with Interferon‐Based RegimensGenetic diversity of NS5A protein from hepatitis C virus genotype 3a and its relationship to therapy responseGenetic heterogeneity of hepatitis C virus in association with antiviral therapy determined by ultra-deep sequencingGenetic Variability of Hepatitis C Virus (HCV) 5' Untranslated Region in HIV/HCV Coinfected Patients Treated with Pegylated Interferon and RibavirinEvasion of intracellular host defence by hepatitis C virusPharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agentsIncreased replicative fitness of a dengue virus 2 clade in native mosquitoes: potential contribution to a clade replacement event in Nicaragua.Evolution of the uniquely adaptable lentiviral envelope in a natural reservoir host.Development of a heterologous, multigenotype vaccine against hepatitis C virus infection.Topology of evolving, mutagenized viral populations: quasispecies expansion, compression, and operation of negative selection.Baseline prediction of combination therapy outcome in hepatitis C virus 1b infected patients by discriminant analysis using viral and host factorsQuasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection.Homogeneity of Powassan virus populations in naturally infected Ixodes scapularis.Identification of HCV Resistant Variants against Direct Acting Antivirals in Plasma and Liver of Treatment Naïve PatientsHepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes.Hepatitis C virus transmission bottlenecks analyzed by deep sequencing.Antiviral potency analysis and functional comparison of consensus interferon, interferon-alpha2a and pegylated interferon-alpha2b against hepatitis C virus infection.Hepatitis C virus quasispecies in chronically infected children subjected to interferon-ribavirin therapyDeep sequencing of hepatitis C virus hypervariable region 1 reveals no correlation between genetic heterogeneity and antiviral treatment outcome
P2860
Q24798391-4A1EF0C2-905D-4068-B841-594AAE7430F1Q26853500-0039F6C9-44B0-4B3F-A247-863DCE5A5E06Q27013917-DE6EE96D-9556-4168-977D-4C39E9E5115DQ27469430-3B09B159-D078-4AA9-86D3-1AF50955ABE8Q27469837-6B387AF1-5DE2-462C-97F7-89280DC042FBQ27470798-B54C1E1E-1145-410A-A951-399A59267E5CQ27472751-3A441BF8-CF91-4139-AD5A-E6BBEA4ACF4DQ27473372-BC790F9B-2D77-4C12-8C9C-6178ED113AC0Q27478062-700E3BE3-0C3F-4657-83C3-D2809C5011A1Q27478102-2FF2F28F-EEE7-473B-AF0C-4911ECD792A0Q27478186-6DEB78DB-3604-40CE-91C6-BDB9B42F6A1CQ27480939-B17E905B-4978-4932-B6F4-B91FA9C10B91Q27485710-72841744-BF8A-45B7-8D71-A60C9A60B398Q27486388-3AE6C40D-FD63-4FB6-ABF5-CF191182A611Q27486521-EE934228-AD79-47C8-988E-46483AEE52C0Q27486537-7BC929AA-6E4A-4199-A095-21EDE480F823Q27486577-345F4573-24B6-46B8-B63F-C10D49E7999CQ27486648-BA0999D8-3EF7-42BC-9EA3-9CF92FF74157Q27488410-7E4F08A2-B0A7-4082-AF04-81FBF581620CQ27490315-71D7726E-F7A0-4AE8-8321-B97DBBFBDEA8Q27490497-59718576-E23A-4474-ABC9-12A6E778D153Q27490972-BEDE13E1-F221-4A43-B63F-98B779CE49E6Q27491275-8FD781CC-AB43-4CE4-9F25-A3CFE09AA41FQ28477175-39E62B1C-04E5-48DC-9428-C8D533CDF629Q28546960-AE8DA13C-1F7A-40CA-AF08-2B2D55C2DD09Q29618976-3E689E6E-7DEE-431B-AF62-7C2F68521478Q30365599-A530903F-55A0-46BC-B879-3D5CB9263626Q30847507-A20F9E69-6DCF-4970-8976-B35A0E5BDD02Q31034710-0EC0758C-EF65-41CC-BD72-1F7AB0498AA3Q33282900-E5F44C44-8F8D-4AD3-A8DA-0A1410D0667FQ33352819-4F29745C-C79E-4DAE-A825-A24EE04DA2B9Q33770280-B371DBFE-99E9-4D49-B8BE-AF4349DF4C43Q33834509-98C31373-D5D9-4B75-8B1C-52B936C61ED2Q33872270-E60D46A1-9186-42D5-B664-6E17124C774AQ33875539-EA9BA242-13B2-456E-B77F-40BD0164CDF9Q33877342-35FF5818-FE57-4160-B707-D78761AEF5A3Q33877425-DDDEA0CB-DAA1-48D7-BAB5-21840AD83E94Q33908879-9A4D9D98-7D44-49CC-A60A-CC404CFC7DBDQ34316603-E898142A-13F2-42C2-B3F9-8D98D2D23878Q34485144-753FEAA3-63C1-43F2-B337-9231F19E166A
P2860
Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Early changes in hepatitis C v ...... redict the therapeutic outcome
@ast
Early changes in hepatitis C v ...... redict the therapeutic outcome
@en
Early changes in hepatitis C v ...... redict the therapeutic outcome
@nl
type
label
Early changes in hepatitis C v ...... redict the therapeutic outcome
@ast
Early changes in hepatitis C v ...... redict the therapeutic outcome
@en
Early changes in hepatitis C v ...... redict the therapeutic outcome
@nl
prefLabel
Early changes in hepatitis C v ...... redict the therapeutic outcome
@ast
Early changes in hepatitis C v ...... redict the therapeutic outcome
@en
Early changes in hepatitis C v ...... redict the therapeutic outcome
@nl
P2093
P2860
P356
P1476
Early changes in hepatitis C v ...... redict the therapeutic outcome
@en
P2093
Alessandra Coiana
Angelo Balestrieri
Daniela Degioannis
Francesco Usai
Giacomo Diaz
Giancarlo Serra
Giovanna Peddis
Harvey J Alter
Luchino Chessa
Patrizia Farci
P2860
P304
P356
10.1073/PNAS.052712599
P407
P577
2002-03-01T00:00:00Z